These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 22500954)
1. Discovery of novel 1,2,4-thiadiazole derivatives as potent, orally active agonists of sphingosine 1-phosphate receptor subtype 1 (S1P(1)). Ren F; Deng G; Wang H; Luan L; Meng Q; Xu Q; Xu H; Xu X; Zhang H; Zhao B; Li C; Guo TB; Yang J; Zhang W; Zhao Y; Jia Q; Lu H; Xiang JN; Elliott JD; Lin X J Med Chem; 2012 May; 55(9):4286-96. PubMed ID: 22500954 [TBL] [Abstract][Full Text] [Related]
2. Discovery of a novel class of zwitterionic, potent, selective and orally active S1P₁ direct agonists. Aguilar N; Mir M; Grima PM; López M; Segarra V; Esteban L; Moreno I; Godessart N; Tarrasón G; Domenech T; Vilella D; Armengol C; Córdoba M; Sabaté M; Casals D; Domínguez M Bioorg Med Chem Lett; 2012 Dec; 22(24):7672-6. PubMed ID: 23141913 [TBL] [Abstract][Full Text] [Related]
3. Identification of benzoxazole analogs as novel, S1P(3) sparing S1P(1) agonists. Deng G; Meng Q; Liu Q; Xu X; Xu Q; Ren F; Guo TB; Lu H; Xiang JN; Elliott JD; Lin X Bioorg Med Chem Lett; 2012 Jun; 22(12):3973-7. PubMed ID: 22583616 [TBL] [Abstract][Full Text] [Related]
4. Discovery of thiadiazole amides as potent, S1P₃-sparing agonists of sphingosine-1-phosphate 1 (S1P₁) receptor. Xu H; Zhang H; Luan L; Xu Y; Li C; Wang Y; Han F; Yang T; Ren F; Xiang JN; Elliott JD; Zhao Y; Guo TB; Lu H; Zhang W; Hirst D; Lindon M; Lin X Bioorg Med Chem Lett; 2012 Apr; 22(7):2456-9. PubMed ID: 22386243 [TBL] [Abstract][Full Text] [Related]
11. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis. Lee CW; Choi JW; Chun J Arch Pharm Res; 2010 Oct; 33(10):1567-74. PubMed ID: 21052934 [TBL] [Abstract][Full Text] [Related]
12. Discovery of 3-arylpropionic acids as potent agonists of sphingosine-1-phosphate receptor-1 (S1P1) with high selectivity against all other known S1P receptor subtypes. Yan L; Huo P; Doherty G; Toth L; Hale JJ; Mills SG; Hajdu R; Keohane CA; Rosenbach MJ; Milligan JA; Shei GJ; Chrebet G; Bergstrom J; Card D; Quackenbush E; Wickham A; Mandala SM Bioorg Med Chem Lett; 2006 Jul; 16(14):3679-83. PubMed ID: 16697189 [TBL] [Abstract][Full Text] [Related]
13. Development of a selective S1P1 receptor agonist, Syl930, as a potential therapeutic agent for autoimmune encephalitis. Jin J; Hu J; Zhou W; Wang X; Xiao Q; Xue N; Yin D; Chen X Biochem Pharmacol; 2014 Jul; 90(1):50-61. PubMed ID: 24780445 [TBL] [Abstract][Full Text] [Related]
14. Optimization of sphingosine-1-phosphate-1 receptor agonists: effects of acidic, basic, and zwitterionic chemotypes on pharmacokinetic and pharmacodynamic profiles. Skidmore J; Heer J; Johnson CN; Norton D; Redshaw S; Sweeting J; Hurst D; Cridland A; Vesey D; Wall I; Ahmed M; Rivers D; Myatt J; Giblin G; Philpott K; Kumar U; Stevens A; Bit RA; Haynes A; Taylor S; Watson R; Witherington J; Demont E; Heightman TD J Med Chem; 2014 Dec; 57(24):10424-42. PubMed ID: 25431977 [TBL] [Abstract][Full Text] [Related]
15. 2,5-Disubstituted pyrrolidine carboxylates as potent, orally active sphingosine-1-phosphate (S1P) receptor agonists. Colandrea VJ; Legiec IE; Huo P; Yan L; Hale JJ; Mills SG; Bergstrom J; Card D; Chebret G; Hajdu R; Keohane CA; Milligan JA; Rosenbach MJ; Shei GJ; Mandala SM Bioorg Med Chem Lett; 2006 Jun; 16(11):2905-8. PubMed ID: 16580205 [TBL] [Abstract][Full Text] [Related]
16. Discovery of potent 3,5-diphenyl-1,2,4-oxadiazole sphingosine-1-phosphate-1 (S1P1) receptor agonists with exceptional selectivity against S1P2 and S1P3. Li Z; Chen W; Hale JJ; Lynch CL; Mills SG; Hajdu R; Keohane CA; Rosenbach MJ; Milligan JA; Shei GJ; Chrebet G; Parent SA; Bergstrom J; Card D; Forrest M; Quackenbush EJ; Wickham LA; Vargas H; Evans RM; Rosen H; Mandala S J Med Chem; 2005 Oct; 48(20):6169-73. PubMed ID: 16190743 [TBL] [Abstract][Full Text] [Related]
17. The utility of pharmacokinetic-pharmacodynamic modeling in the discovery and optimization of selective S1P(1) agonists. Taylor S; Gray JR; Willis R; Deeks N; Haynes A; Campbell C; Gaskin P; Leavens K; Demont E; Dowell S; Cryan J; Morse M; Patel A; Garden H; Witherington J Xenobiotica; 2012 Jul; 42(7):671-86. PubMed ID: 22225501 [TBL] [Abstract][Full Text] [Related]
19. Potent S1P receptor agonists replicate the pharmacologic actions of the novel immune modulator FTY720. Hale JJ; Neway W; Mills SG; Hajdu R; Ann Keohane C; Rosenbach M; Milligan J; Shei GJ; Chrebet G; Bergstrom J; Card D; Koo GC; Koprak SL; Jackson JJ; Rosen H; Mandala S Bioorg Med Chem Lett; 2004 Jun; 14(12):3351-5. PubMed ID: 15149705 [TBL] [Abstract][Full Text] [Related]
20. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Chiba K Pharmacol Ther; 2005 Dec; 108(3):308-19. PubMed ID: 15951022 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]